Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | CSK | P41240 | 1/20 | 0.38 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1989554 | 0.86 | ADRA1A (0.47) | PTGDR2ALDH1A1MEN1KMT2APARP1 | |
| SCHEMBL1992571 | 0.84 | SMN1; SMN2 (0.48) | PTGDR2ALDH1A1 | |
| SCHEMBL1990506 | 0.83 | CHRM2 (0.47) | BTK | |
| SCHEMBL12564065 | 0.82 | ABCB1 (0.43) | PTGDR2ALDH1A1MEN1KMT2APARP1 | |
| Hydrochloric Acid SCHEMBL1991841 | 0.81 | ABCB1 (0.43) | PTGDR2ALDH1A1MEN1KMT2APARP1 | |
| SCHEMBL1993222 | 0.80 | PTGDR2 (0.41) | PTGDR2 | |
| SCHEMBL1993220 | 0.80 | PTGDR2 (0.41) | PTGDR2 | |
| SCHEMBL29129990 | 0.72 | BTK (0.43) | ALDH1A1MEN1KMT2ALCKCSK | |
| SCHEMBL29129988 | 0.72 | BTK (0.43) | ALDH1A1MEN1KMT2ALCKCSK | |
| SCHEMBL2002226 | 0.71 | L3MBTL1 (0.50) | ALDH1A1MEN1KMT2ABTKCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011079105-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | PTGDR2 61/4885ALDH1A1 297/4885MEN1 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.